Director Ravi Sarin resigns from The Oncology Institute board; no disagreement cited

Oncology Institute, Inc.

Ravi Sarin resigned from the Board on August 31, 2023, effective immediately.
Resignation not related to any disagreement with the Company on operations, policies, or practices.
Sarin served on Audit, Compensation, and Compliance Committees; replacements to be considered.
Board size reduced to eight directors following Mr. Sarin's departure.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Ravi Sarin

Director

TOI · Oncology Institute, Inc.

Effective: 2023-08-31
Filed: September 1, 2023, 7:59 PM ET

On August 31, 2023, Ravi Sarin, a member of the Board of Directors (the “Board”) of The Oncology Institute, Inc. (the “Company”), resigned effective immediately as a director of the Board, including any positions held as a member of any committee of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Ravi Sarin resigned as Director at Oncology Institute, Inc..

Action: resigned
Role: Director

Exact text from the filing

On August 31, 2023, Ravi Sarin, a member of the Board of Directors (the “Board”) of The Oncology Institute, Inc. (the “Company”), resigned effective immediately as a director of the Board, including any positions held as a member of any committee of the Board.

View on SEC.gov

Oncology Institute, Inc. filing history →

Source: SEC EDGAR

accession 0001799191-23-000042

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.